[go: up one dir, main page]

WO1995009005B1 - Procede de stimulation de la synthese de l'interleukine-6 et d'induction de la thrombocytopoiese a l'aide d'oncostatine m - Google Patents

Procede de stimulation de la synthese de l'interleukine-6 et d'induction de la thrombocytopoiese a l'aide d'oncostatine m

Info

Publication number
WO1995009005B1
WO1995009005B1 PCT/US1994/010923 US9410923W WO9509005B1 WO 1995009005 B1 WO1995009005 B1 WO 1995009005B1 US 9410923 W US9410923 W US 9410923W WO 9509005 B1 WO9509005 B1 WO 9509005B1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
oncostatin
interleukin
methods
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/010923
Other languages
English (en)
Other versions
WO1995009005A1 (fr
Filing date
Publication date
Priority claimed from US08/312,205 external-priority patent/US5814307A/en
Application filed filed Critical
Priority to AU78447/94A priority Critical patent/AU7844794A/en
Priority to JP7510413A priority patent/JPH09505560A/ja
Priority to EP94929361A priority patent/EP0721344A1/fr
Publication of WO1995009005A1 publication Critical patent/WO1995009005A1/fr
Publication of WO1995009005B1 publication Critical patent/WO1995009005B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

La présente invention a pour objet des procédés d'utilisation de l'oncostatine-M (OM). Elle concerne en particulier l'utilisation d'OM pour stimuler la synthèse d'interleukine-6 (IL-6) dans des cellules cibles, en particulier des cellules endothéliales humaines. L'IL-6 ainsi produite peut exécuter diverses fonctions telles que la régulation de la croissance cellulaire, la différenciation des leucocytes et l'inhibition des tumeurs. La présente invention se rapporte en outre à l'utilisation de l'OM pour traiter les cytopénies, y compris l'anémie et la thrombocytopoïèse, et pour augmenter la tolérance aux rayonnements et aux médicaments cytotoxiques. Les procédés selon l'invention permettent donc des utilisations variées, notamment, mais non exclusivement, l'inhibition de la croissance tumorale, le traitement des cytopénies, et l'augmentation de la tolérance à la radiothérapie et à la chimiothérapie. L'OM peut être utilisée en association avec diverses cytokines, notamment l'érythropoïétine, les facteurs de stimulation de colonies, l'interleukine-3 ou la thrombopoïétine.
PCT/US1994/010923 1993-09-29 1994-09-27 Procede de stimulation de la synthese de l'interleukine-6 et d'induction de la thrombocytopoiese a l'aide d'oncostatine m Ceased WO1995009005A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU78447/94A AU7844794A (en) 1993-09-29 1994-09-27 Methods for stimulating interleukin-6 synthesis and inducing thrombocytopoiesis using oncostatin m
JP7510413A JPH09505560A (ja) 1993-09-29 1994-09-27 オンコスタチンｍを用いるインターロイキン−６合成刺激方法および血小板産生誘発方法
EP94929361A EP0721344A1 (fr) 1993-09-29 1994-09-27 Procede de stimulation de la synthese de l'interleukine-6 et d'induction de la thrombocytopoiese a l'aide d'oncostatine m

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12923093A 1993-09-29 1993-09-29
US129,230 1994-09-26
US08/312,205 US5814307A (en) 1989-04-10 1994-09-26 Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US08/312,205 1994-09-26

Publications (2)

Publication Number Publication Date
WO1995009005A1 WO1995009005A1 (fr) 1995-04-06
WO1995009005B1 true WO1995009005B1 (fr) 1995-05-04

Family

ID=26827388

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/010923 Ceased WO1995009005A1 (fr) 1993-09-29 1994-09-27 Procede de stimulation de la synthese de l'interleukine-6 et d'induction de la thrombocytopoiese a l'aide d'oncostatine m

Country Status (6)

Country Link
US (1) US5814307A (fr)
EP (1) EP0721344A1 (fr)
JP (1) JPH09505560A (fr)
AU (1) AU7844794A (fr)
CA (1) CA2172808A1 (fr)
WO (1) WO1995009005A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075316A1 (fr) * 1999-06-02 2000-12-14 Genentech, Inc. Procedes et compositions pour l'inhibition de la croissance de cellules neoplastiques
WO2000021996A2 (fr) * 1998-10-13 2000-04-20 Genentech, Inc. Procedes et compositions inhibant la croissance des cellules neoplasiques
HU227708B1 (en) * 1994-10-21 2011-12-28 Chugai Pharmaceutical Co Ltd Use of anti-interleukin-6-receptor antibodies mr-16 and pm-1 and derivatives thereof for producing pharmaceutical preparation for treating diseases caused by il-6 production
EP0748870A3 (fr) * 1995-06-06 1997-03-26 Bristol Myers Squibb Co L'Hematopoiese induite par l'oncostatine M
EP0871472A4 (fr) * 1995-10-27 2001-05-30 Amrad Operations Pty Ltd Cytokines et leur utilisation dans le traitement et/ou la prophylaxie du cancer du sein
WO2000053751A1 (fr) * 1999-03-08 2000-09-14 Genentech, Inc. Procedes et compositions pour l'inhibition de la croissance de cellules neoplasiques
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
JP2002531092A (ja) * 1998-12-01 2002-09-24 ジェネンテック・インコーポレーテッド 腫瘍性細胞成長阻害のための組成物及び方法
EP2075335A3 (fr) * 1998-12-22 2009-09-30 Genentech, Inc. Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
DK1484338T3 (da) * 1998-12-22 2007-06-11 Genentech Inc Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst
AU1749800A (en) * 1999-03-12 2000-10-04 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
EP1873244A3 (fr) * 1999-06-02 2008-04-02 Genentech, Inc. Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
CA2373915A1 (fr) * 1999-06-02 2000-12-07 Genentech, Inc. Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
AU3246100A (en) * 1999-06-02 2000-12-28 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
EP1244784A2 (fr) * 2000-01-06 2002-10-02 Genentech, Inc. Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
EA007481B1 (ru) * 2001-09-24 2006-10-27 Тоск, Инк. Цисплатиновые составы пониженной токсичности и способы их применения
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
WO2007149328A1 (fr) * 2006-06-20 2007-12-27 Genzyme Corporation Milieux asériques et utilisations pour l'expansion de chondrocytes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6463395A (en) * 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
IL112766A (en) * 1989-04-10 1996-06-18 Oncogen Pharmaceutical preparations containing oncostatin M intended for increased fibrinolysis and thrombolysis
US5202116A (en) * 1989-04-10 1993-04-13 Oncogen Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
US5744442A (en) * 1992-08-26 1998-04-28 Bristol Meyers Squibb Company Regulation of cellular invasiveness
US5460810A (en) * 1992-09-02 1995-10-24 Genetics Institute, Inc. Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11

Similar Documents

Publication Publication Date Title
WO1995009005B1 (fr) Procede de stimulation de la synthese de l'interleukine-6 et d'induction de la thrombocytopoiese a l'aide d'oncostatine m
Uckun et al. In vivo radioprotective effects of recombinant human granulocyte colony-stimulating factor in lethally irradiated mice
Weisbart et al. Physiology of granulocyte and macrophage colony-stimulating factors in host defense.
Ogawa Effects of hemopoietic growth factors on stem cells in vitro
ATE71662T1 (de) Einen menschlichen granulozytkoloniereizfaktor fuer die behandlung von leukopenien enthaltende pharmazeutische zubereitung.
Baatout Interleukin-6 and megakaryocytopoiesis: an update
ES2039209T5 (es) Compuesto farmaceutico que promueve el restablecimiento de la capacidad hemopoyetica.
Hamblin Lymphokines and interleukins
EP0325471A1 (fr) Procédé pour supprimer la croissance de cellules normales et cancéreuses
Rowe et al. Hematopoietic growth factors in acute leukemia
Rinehart et al. Phase 1 trial of recombinant human interleukin-1β (rhIL-1β), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology Group Study 8940
Van Der Lely et al. Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells
Constine et al. Interleukin 1 alpha stimulates hemopoiesis but not tumor cell proliferation and protects mice from lethal total body irradiation
Slørdal et al. Radioprotection by murine and human tumor‐necrosis factor: Dose‐dependent effects on hematopoiesis in the mouse
Gabrilove et al. Granulocyte colony-stimulating factor: preclinical and clinical studies
Ishizuka et al. Low molecular weight immunomodulators produced by microorganisms
Maury Anaemia in rheumatoid arthritis: role of cytokines
Obradovich et al. Effect of Recombinant Canine Granulocyte Colony‐stimulating Factor on Peripheral Blood Neutrophil Counts in Normal Cats
KAWATSU et al. Effect of conagenin on thrombocytopenia induced by antitumor agents in mice
Veldhuis et al. Potential use of recombinant human interleukin-6 in clinical oncology
Misawa et al. Effects of macrophage colony-stimulating factor and interleukin-2 administration on NK1. 1+ cells in mice
RU2647833C1 (ru) Гемостимулирующее средство
Mitsuyasu et al. Clinical role of granulocyte-macrophage colony-stimulating factor
Tefferi et al. Current perspective in agnogenic myeloid metaplasia
Smith Use of hematopoietic growth factors for treatment of aplastic anemia